Test Price
2,800 AED✅ Home Collection Available
MYOZ2 Gene (Familial Hypertrophic Cardiomyopathy Type 16) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Diagnostic Accuracy: 99.9% sensitivity for pathogenic variants in MYOZ2 via ISO 9001:2015 accredited next‑generation sequencing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic post‑test consultation by DHA‑licensed specialist in medical genetics.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This next-generation sequencing (NGS) test analyzes the MYOZ2 gene for pathogenic and likely pathogenic variants associated with familial hypertrophic cardiomyopathy type 16 (CMH16). The assay covers the entire coding region, splice junctions, and detects single nucleotide variants, small insertions/deletions, and copy number variations using an Illumina® platform with validated bioinformatics. Results are interpreted according to ACMG/AMP guidelines and integrated with clinical findings for precise diagnosis and family risk stratification.
| Feature | Our NGS Test | Conventional Sanger Sequencing |
|---|---|---|
| Precision | High‑depth coverage (>99% of coding region, CNV detection) | Exon‑by‑exon; may miss large deletions/duplications |
| Method | Next‑Generation Sequencing (Illumina®) | Sanger sequencing (single‑gene, limited throughput) |
| Turnaround Time | 3–4 weeks (with clinical review) | 4–6 weeks (often delayed by sequential exon testing) |
Physician Insight & Safety Protocols
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue or alter any prescribed medication without consulting your treating cardiologist. Genetic test results are meant to guide long‑term management and should be integrated into your overall care plan by a qualified physician.
Patient Safety: Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Inability to provide a blood sample; lack of informed consent for genetic testing; individuals under 18 years without court‑authorised guardian consent (in compliance with Federal Decree‑Law No. 4 of 2016 on Medical Liability).
- Emergency Red Flags: Sudden chest pain, severe shortness of breath, fainting (syncope), or palpitations require immediate emergency medical attention. Genetic test results do not replace urgent clinical assessment.
Patient FAQ & Clinical Guidance
1. What exactly does the MYOZ2 gene test detect?
Answer: The MYOZ2 NGS test identifies pathogenic or likely pathogenic variants in the MYOZ2 gene causing familial hypertrophic cardiomyopathy type 16. It sequences the full coding region and splice junctions, detecting single nucleotide changes, small insertions/deletions, and copy number variations, enabling precise molecular diagnosis and differentiation from other genetic cardiomyopathies.
2. Who are the ideal candidates for this genetic test?
Answer: Ideal candidates include individuals with a clinical diagnosis of hypertrophic cardiomyopathy, those with a family history of unexplained sudden cardiac death or HCM, and asymptomatic relatives seeking risk clarification. A mandatory pre‑test genetic counselling session will construct a detailed pedigree and obtain informed consent.
3. How long does it take to receive the results and what happens next?
Answer: Results are typically available within 3 to 4 weeks. You will receive a telephonic post‑test consultation with a DHA‑licensed medical genetics specialist who will explain the findings, recommend cardiac surveillance, family testing, and lifestyle modifications. Positive results often trigger cascade screening in at‑risk relatives; negative results require continued clinical follow‑up if there is a strong family history.
UAE Regulatory & Data Privacy Adherence
- ✅ Full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) for genetic data confidentiality.
- ✅ Adheres to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for secure handling of health information.
- ✅ ISO 9001:2015 Certified – Quality Management System (Cert: INT/EGQ/2509DA/3139).
- ✅ Operates under DHA Facility License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | MYOZ2 Gene (Familial Hypertrophic Cardiomyopathy Type 16) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (3–5 mL) in EDTA tube |
| Methodology Used | Next‑Generation Sequencing (Illumina® platform) |
| ICD‑10‑CM Code | I42.2 (Hypertrophic cardiomyopathy) |
| LOINC Code | 93929-0 (MYOZ2 gene mutation analysis in Blood or Tissue by NGS) |
| DHA Facility License & Laboratory Address | License No. 1143 | DNA Labs UAE – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians